

Sierra Leone has stopped mass drug administration (MDA) for lymphatic filariasis in 75% of endemic districts in the country following the likely interruption of transmission of the causative parasite in 12 districts as of FY21 (October 2020 – September 2021). Prevalence of infection has been reduced significantly in the remaining four districts due to ongoing MDA.

There are nine SCH/STH-endemic districts in Sierra Leone. Following up to ten rounds of high coverage MDA, a schistosomiasis/soil-transmitted helminthiasis (SCH/STH) impact assessment was conducted in all districts in 2022. A data review meeting will be held in February 2023 to review the data from this survey to assess whether treatment threshold have been met (less than 10% prevalence) and for the country to assess treatment strategies.
Standard Disease-Specific Indicators as of FY21
FY21 is October 2020 through September 2021

of ever-endemic districts have stopped MDA as of FY21
(i.e. have passed stop MDA survey, TAS1 (First Transmission Assessment Survey))
of ever-endemic districts in post-surveillance phase as of FY21
(i.e. have passed last surveillance survey, TAS3 (third Transmission Assessment Survey))
of persons no longer at risk as of FY21 among those who were ever at risk
Trachoma is not endemic in Sierra Leone.

of ever endemic districts have been treated at least once as of FY21
(in cases where a country has more treated districts reported than, ever endemic, the adjusted percent is 100%)

of ever endemic districts have been treated at least once as of FY21
